Comparing Cynosure (CYNO) & Its Rivals

Cynosure (NASDAQ: CYNO) is one of 76 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Cynosure to similar companies based on the strength of its analyst recommendations, risk, dividends, valuation, profitability, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Cynosure and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cynosure 0 3 1 0 2.25
Cynosure Competitors 271 1866 3325 105 2.59

Cynosure currently has a consensus target price of $58.00, indicating a potential downside of 12.32%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 9.64%. Given Cynosure’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Cynosure has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Cynosure and its competitors revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Cynosure N/A N/A 110.25
Cynosure Competitors $2.14 billion $229.91 million -29.42

Cynosure’s competitors have higher revenue and earnings than Cynosure. Cynosure is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Cynosure and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cynosure 0.70% 0.75% 0.59%
Cynosure Competitors -152.97% -24.74% -8.93%

Insider & Institutional Ownership

50.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 2.9% of Cynosure shares are owned by company insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


Cynosure competitors beat Cynosure on 7 of the 10 factors compared.

Cynosure Company Profile

Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply